Derma Sciences Inc. (DSCI) Rating Lowered to Sell at Zacks Investment Research
Derma Sciences Inc. (NASDAQ:DSCI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded Derma Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Derma Sciences currently has an average rating of “Hold” and a consensus target price of $8.06.
Derma Sciences (NASDAQ:DSCI) opened at 4.35 on Tuesday. Derma Sciences has a 12 month low of $2.85 and a 12 month high of $5.86. The company’s 50-day moving average price is $4.62 and its 200-day moving average price is $4.40. The stock’s market cap is $123.13 million.
Derma Sciences (NASDAQ:DSCI) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The company had revenue of $21.80 million for the quarter, compared to analysts’ expectations of $23.90 million. Derma Sciences had a negative net margin of 12.32% and a negative return on equity of 4.09%. Equities analysts forecast that Derma Sciences will post ($0.12) earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in DSCI. Jacobs Levy Equity Management Inc. boosted its stake in Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock worth $364,000 after buying an additional 73,911 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in Derma Sciences during the second quarter worth $202,000. Dimensional Fund Advisors LP boosted its stake in Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock worth $207,000 after buying an additional 7,086 shares in the last quarter. Vanguard Group Inc. boosted its stake in Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock worth $3,163,000 after buying an additional 8,376 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock worth $603,000 after buying an additional 3,613 shares in the last quarter. Institutional investors and hedge funds own 62.56% of the company’s stock.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Stock Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related stocks with our FREE daily email newsletter.